ICER releases new tools to facilitate use of its reports

Influential US pricing watchdog the Institute for Clinical and Economic Review (ICER) has announced the development of two new tools for payers, pharma firms and others to access its cost-effectiveness analyses.

The new decision-support tools – the ICER Evidence Compendium and the ICER Interactive Modeler – will be subscription-based products intended to make past and present ICER work easier to search and analyze.

Commenting on the new tools, President Steven Pearson said: “With these advancements, the US health system will be able to more effectively integrate and systematize ICER assessments, so that evidence can be used in a more transparent way to better align a treatment’s price to its ability to improve patients’ lives.”